Key result
Operation in patients with cancer increases the risk of thromboembolic complications two to three fold, and pharmacologic prophylaxis with heparin or LMWH is recommended.
Why the study?
Do pharmacologic methods (low-dose unfractionated heparin and low molecular weight heparin) prevent thromboembolic disease in cancer surgical patients?
Population
Cancer surgical patients
Design
Review
Authors
Loading...
May support in-hospital heparin prophylaxis after cancer surgery; leaves open extended regimens.
Do pharmacologic methods (low-dose unfractionated heparin and low molecular weight heparin) prevent thromboembolic disease in cancer surgical patients?
Pharmacologic thromboprophylaxis with LDUH or LMWH is recommended for cancer surgical patients during hospitalization and post-discharge for high-risk individuals.
Ajay K. Kakkar (2009) conducted a review in Venous thromboembolism in cancer surgical patients. Pharmacologic thromboprophylaxis (low-dose unfractionated heparin and low molecular weight heparin) was evaluated. Operation in patients with cancer increases the risk of thromboembolic complications two to three fold, and pharmacologic prophylaxis with heparin or LMWH is recommended.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: